Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the ...
Serious adverse events occurred in 51.2 and 21.9% of patients receiving melphalan/hepatic delivery system and BAC, respectively. HealthDay News — For patients with unresectable metastatic uveal ...
NEW YORK, Jan. 31, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today ...
By recreating a fetal liver niche, FLOs show how liver and immune cells co-develop. Learn more about new groundbreaking ...
Melphalan/HDS treatment for patients with hepatic dominant metastatic uveal melanoma: Results from an expanded access program.
Hepatic adenoma is an uncommon, benign liver tumor. Benign means that it’s not cancerous. It’s also known as hepatocellular adenoma or liver cell adenoma. Hepatic adenoma is extremely rare. It most ...
THE liver acts as a selective barrier between the gastrointestinal tract and the systemic circulation, metabolizing, detoxifying and elaborating for further physiologic disposition various substances ...
Congenital hepatic fibrosis is a type of liver disease that is present from birth. It typically affects the function of the bile ducts and the veins that carry blood from the digestive tract to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback